{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:01:52Z","timestamp":1793826112555,"version":"4.6.1"},"reference-count":132,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Chikungunya Virus (CHIKV), an enveloped RNA virus transmitted by\nAedes mosquitoes, has become an increasing global health concern, particularly in South America,\nwhere cases and fatalities have risen (PAHO, 2023). This review focuses on therapeutic strategies\ntargeting the CHIKV E2 protein, including vaccines, antibodies, and antiviral approaches tested in\nvitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Literature reporting on the E2 protein, including studies on viral structure, host interactions,\nsymptoms, and treatments under development, was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The E2 protein, a major structural component of CHIKV, is critical for viral entry and virulence,\nmediating interactions with host factors (Glycosaminoglycans (GAGs) and C-type lectins) and\nreceptors (Matrix Remodeling-Associated Protein 8 (Mxra8) and Prohibitin-1 (PHB1)). It also elicits\nrobust antibody responses, making it a key target for therapeutic intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The E2 protein is essential for CHIKV entry and virulence, making it a key target for\nvaccines, antibodies, and antivirals. While preclinical studies show promise, efficacy varies and clinical\ntranslation remains limited. Challenges include viral diversity, immune escape, and the need for\nintegrated strategies combining different therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Given the absence of licensed vaccines and antivirals for alphaviruses, the E2 protein\nrepresents a promising therapeutic target while inhibiting E2 could block viral entry and infection.\nHowever, current strategies show variable efficacy and inconclusive results, highlighting the need for\nfurther research to validate and optimize E2-targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113894501436868260120100843","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:55:10Z","timestamp":1774439710000},"page":"658-677","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["E2 Protein of Chikungunya Virus: A Narrative Review of Its Potential as a Therapeutic Target"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4047-3975","authenticated-orcid":true,"given":"Kelly Megumi","family":"Yaekashi","sequence":"first","affiliation":[{"name":"Department of Immunology, Parasitology and General Pathology, Laboratory of Pain, Inflammation, Neuropathy and Cancer, Londrina State University, Londrina, Paran\u00e1 86057-970, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0842-5965","authenticated-orcid":true,"given":"Jessica Aparecida","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Department of Immunology, Parasitology and General Pathology, Laboratory of Pain, Inflammation, Neuropathy and Cancer, Londrina State University, Londrina, Paran\u00e1 86057-970, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-950X","authenticated-orcid":true,"given":"Geovana","family":"Martelossi-Cebinelli","sequence":"additional","affiliation":[{"name":"Department of Immunology, Parasitology and General Pathology, Laboratory of Pain, Inflammation, Neuropathy and Cancer, Londrina State University, Londrina, Paran\u00e1 86057-970, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0551-4313","authenticated-orcid":true,"given":"Mariana Marques","family":"Bertozzi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Center of Health Science, Londrina State University, Londrina, Paran\u00e1 86038-440, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-7457","authenticated-orcid":true,"given":"Mariana Stinglin Rosa","family":"Ribas","sequence":"additional","affiliation":[{"name":"Department of Immunology, Parasitology and General Pathology, Laboratory of Pain, Inflammation, Neuropathy and Cancer, Londrina State University, Londrina, Paran\u00e1 86057-970, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-9105","authenticated-orcid":true,"given":"Camila","family":"Zanluca","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Virology, Carlos Chagas Institute\/ Fiocruz PR, Curitiba 81350-010, PR, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8707-6638","authenticated-orcid":true,"given":"Claudia N. Duarte","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Virology, Carlos Chagas Institute\/ Fiocruz PR, Curitiba 81350-010, PR, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-1668","authenticated-orcid":true,"given":"Rubia","family":"Casagrande","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Center of Health Science, Londrina State University, Londrina, Paran\u00e1 86038-440, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-9283","authenticated-orcid":true,"given":"Waldiceu A.","family":"Verri","sequence":"additional","affiliation":[{"name":"Department of Immunology, Parasitology and General Pathology, Laboratory of Pain, Inflammation, Neuropathy and Cancer, Londrina State University, Londrina, Paran\u00e1 86057-970, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/v14050969","volume":"14","author":"de Lima Cavalcanti T.Y.V.","year":"2022","unstructured":"de Lima Cavalcanti T.Y.V.; Pereira M.R.; de Paula S.O.; Franca R.F.O.; A review on chikungunya virus epidemiology, pathogenesis and current vaccine development. Viruses  2022,14(5),969","journal-title":"Viruses"},{"key":"ref=2","year":"2024","unstructured":"Epidemiological Update \u2013 Chikungunya in the Region of the Americas \u2013 22 April 2024.  Available from:  https:\/\/www.paho.org\/en\/documents\/epidemiological-update-chikungunya-region-americas-22-april-20242024"},{"key":"ref=3","year":"2025","unstructured":"Chikungunya virus disease worldwide overview.  Available from:  https:\/\/www.ecdc.europa.eu\/en\/chikungunya-monthly2025"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"105610","DOI":"10.1016\/j.jcv.2023.105610","volume":"169","author":"Martins E.B.","year":"2023","unstructured":"Martins E.B.; Quintana M.S.B.; Silva M.F.B.; Predictors of chronic joint pain after Chikungunya virus infection in the INOVACHIK prospective cohort study. J Clin Virol  2023,169,105610","journal-title":"J Clin Virol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ijid.2021.03.003","volume":"105","author":"Silva M.M.O.","year":"2021","unstructured":"Silva M.M.O.; Kikuti M.; Anjos R.O.; Risk of chronic arthralgia and impact of pain on daily activities in a cohort of patients with chikungunya virus infection from Brazil. Int J Infect Dis  2021,105,608-616","journal-title":"Int J Infect Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/cells12040556","volume":"12","author":"Segato-Vendrameto C.Z.","year":"2023","unstructured":"Segato-Vendrameto C.Z.; Zanluca C.; Zucoloto A.Z.; Chikungunya virus and its envelope protein E2 induce hyperalgesia in mice: Inhibition by Anti-E2 monoclonal antibodies and by targeting TRPV1. Cells  2023,12(4),556","journal-title":"Cells"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2301573","DOI":"10.1080\/21505594.2023.2301573","volume":"15","author":"Ly H.","year":"2024","unstructured":"Ly H.; Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection. Virulence  2024,15(1),2301573","journal-title":"Virulence"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"0341","DOI":"10.1590\/0037-8682-0341-2023","volume":"56","author":"Oliveira J.L.","year":"2023 Dec 8","unstructured":"Oliveira J.L.; Nogueira I.A.; Amaral J.K.; Extra-articular manifestations of chikungunya. Rev Soc Bras Med Trop  2023 Dec 8,56,0341","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1741-7015-9-5","volume":"9","author":"G\u00e9rardin P.","year":"2011  Jan 14","unstructured":"G\u00e9rardin P.; Fianu A.; Malvy D.; Perceived morbidity and community burden after a Chikungunya outbreak: the TELECHIK survey, a population-based cohort study. BMC Med  2011  Jan 14,9,5","journal-title":"BMC Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"101618","DOI":"10.1016\/j.tmaid.2020.101618","volume":"35","author":"Noor F.M.","year":"2020","unstructured":"Noor F.M.; Hossain M.B.; Islam Q.T.; Prevalence of and risk factors for long-term disabilities following chikungunya virus disease: A meta-analysis. Travel Med Infect Dis  2020,35,101618","journal-title":"Travel Med Infect Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"108193","DOI":"10.1016\/j.ijid.2025.108193","volume":"163","author":"Foga\u00e7a M.M.C.","year":"2026","unstructured":"Foga\u00e7a M.M.C.; Souza M.S.; Brito R.D.S.; Genetic polymorphisms in the E2 glycoprotein of chikungunya virus (2014-2023) and their potential implications for immunity and vaccine design. Int J Infect Dis  2026,163,108193","journal-title":"Int J Infect Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1038\/s41467-022-32431-9","volume":"13","author":"Mangala Prasad V.","year":"2022","unstructured":"Mangala Prasad V.; Blijleven J.S.; Smit J.M.; Lee K.K.; Visualization of conformational changes and membrane remodeling leading to genome delivery by viral class-II fusion machinery. Nat Commun  2022,13(1),4772","journal-title":"Nat Commun"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41564-022-01164-2","volume":"7","author":"Chmielewski D.","year":"2022","unstructured":"Chmielewski D.; Schmid M.F.; Simmons G.; Jin J.; Chiu W.; Chikungunya virus assembly and budding visualized in situ using cryogenic electron tomography. Nat Microbiol  2022,7(8),1270-9","journal-title":"Nat Microbiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-virology-093022-010359","volume":"12","author":"Luo D.","year":"2025","unstructured":"Luo D.; Tan Y.B.; Law M.C.Y.; Jin J.; A structural perspective on the alphavirus life cycle. Annu Rev Virol  2025,12(1),299-314","journal-title":"Annu Rev Virol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12929-021-00778-8","volume":"28","author":"Khongwichit S.","year":"2021 Dec 2","unstructured":"Khongwichit S.; Chansaenroj J.; Chirathaworn C.; Poovorawan Y.; Chikungunya virus infection: molecular biology, clinical characteristics, and epidemiology in Asian countries. J Biomed Sci  2021 Dec 2,28(1),84","journal-title":"J Biomed Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrmicro2368","volume":"8","author":"Schwartz O.","year":"2010","unstructured":"Schwartz O.; Albert M.L.; Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol  2010,8(7),491-500","journal-title":"Nat Rev Microbiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1146\/annurev-virology-091919-102021","volume":"8","author":"Kril V.","year":"2021","unstructured":"Kril V.; A\u00efqui-Reboul-Paviet O.; Briant L.; Amara A.; New insights into chikungunya virus infection and pathogenesis. Annu Rev Virol  2021,8(1),327-47","journal-title":"Annu Rev Virol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.coviro.2016.02.007","volume":"16","author":"Tsetsarkin K.A.","year":"2016","unstructured":"Tsetsarkin K.A.; Chen R.; Weaver S.C.; Interspecies transmission and chikungunya virus emergence. Curr Opin Virol  2016,16(12),143-50","journal-title":"Curr Opin Virol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.4269\/ajtmh.17-0126","volume":"97","author":"Eastwood G.","year":"2017","unstructured":"Eastwood G.; Sang R.C.; Guerbois M.; Taracha E.L.N.; Weaver S.C.; Enzootic circulation of chikungunya virus in east africa: serological evidence in non-human kenyan primates. Am J Trop Med Hyg  2017,97(5),1399-404","journal-title":"Am J Trop Med Hyg"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41467-018-03332-7","volume":"9","author":"Althouse B.M.","year":"2018","unstructured":"Althouse B.M.; Guerbois M.; Cummings D.A.T.; Role of monkeys in the sylvatic cycle of chikungunya virus in Senegal. Nat Commun  2018,9(1),1046","journal-title":"Nat Commun"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4269\/ajtmh.1999.60.281","volume":"60","author":"Diallo M.","year":"1999","unstructured":"Diallo M.; Thonnon J.; Traore-Lamizana M.; Fontenille D.; Vectors of Chikungunya virus in Senegal: current data and transmission cycles. Am J Trop Med Hyg  1999,60(2),281-6","journal-title":"Am J Trop Med Hyg"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e1649","DOI":"10.1371\/journal.pntd.0001649","volume":"6","author":"Diallo D.","year":"2012","unstructured":"Diallo D.; Sall A.A.; Buenemann M.; Landscape ecology of sylvatic chikungunya virus and mosquito vectors in southeastern Senegal. PLoS Negl Trop Dis  2012,6(6),e1649","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"102168","DOI":"10.1016\/j.tmaid.2021.102168","volume":"44","author":"Kumar R.","year":"2021","unstructured":"Kumar R.; Ahmed S.; Parray H.A.; Das S.; Chikungunya and arthritis: An overview. Travel Med Infect Dis  2021,44,102168","journal-title":"Travel Med Infect Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e0249166","DOI":"10.1371\/journal.pone.0249166","volume":"16","author":"Ferreira F.C.P.A.D.M.","year":"2021","unstructured":"Ferreira F.C.P.A.D.M.; da Silva A.S.V.; Recht J.; Vertical transmission of chikungunya virus: A systematic review. PLoS One  2021,16(4),e0249166","journal-title":"PLoS One"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1371\/journal.ppat.0040029","volume":"4","author":"Couderc T.","year":"2008","unstructured":"Couderc T.; Chr\u00e9tien F.; Schilte C.; A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog  2008,4(2),e29","journal-title":"PLoS Pathog"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/art.40403","volume":"70","author":"Zaid A.","year":"2018","unstructured":"Zaid A.; G\u00e9rardin P.; Taylor A.; Mostafavi H.; Malvy D.; Mahalingam S.; Review: Chikungunya Arthritis: Implications of Acute and chronic inflammation mechanisms on disease management. Arthritis Rheumatol  2018,70(4),484-95","journal-title":"Arthritis Rheumatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"106872","DOI":"10.1016\/j.actatropica.2023.106872","volume":"241","author":"Silva A.C.","year":"2023","unstructured":"Silva A.C.; Silva A.C.; de Castro P.A.S.V.; \u00c1vila I.R.; Bezerra J.M.T.; Prevalence and epidemiological aspects of Chikungunya fever in states of the Northeast region of Brazil: A systematic review. Acta Trop  2023,241,106872","journal-title":"Acta Trop"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"882","DOI":"10.4269\/ajtmh.13-0403","volume":"90","author":"Rudolph K.E.","year":"2014","unstructured":"Rudolph K.E.; Lessler J.; Moloney R.M.; Kmush B.; Cummings D.A.T.; Incubation periods of mosquito-borne viral infections: a systematic review. Am J Trop Med Hyg  2014,90(5),882-91","journal-title":"Am J Trop Med Hyg"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/tmi.13711","volume":"27","author":"Vidal E.R.N.","year":"2022","unstructured":"Vidal E.R.N.; Frutuoso L.C.V.; Duarte E.C.; Peixoto H.M.; Epidemiological burden of Chikungunya fever in Brazil, 2016 and 2017. Trop Med Int Health  2022,27(2),174-84","journal-title":"Trop Med Int Health"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.medmal.2015.05.007","volume":"45","author":"Simon F.","year":"2015","unstructured":"Simon F.; Javelle E.; Cabie A.; French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect  2015,45(7),243-63","journal-title":"Med Mal Infect"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.htct.2018.04.002","volume":"40","author":"Slavov S.N.","year":"2018","unstructured":"Slavov S.N.; Otaguiri K.K.; Bianquini M.L.; Seroprevalence of Chikungunya virus in blood donors from Northern and Southeastern Brazil. Hematol Transfus Cell Ther  2018,40(4),358-62","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e0006919","DOI":"10.1371\/journal.pntd.0006919","volume":"13","author":"Rezza G.","year":"2019  Jan 17","unstructured":"Rezza G.; Weaver S.C.; Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development. PLoS Negl Trop Dis  2019  Jan 17,13(1),e0006919","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e3066","DOI":"10.1371\/journal.pone.0003066","volume":"3","author":"Sissoko D.","year":"2008","unstructured":"Sissoko D.; Moendandze A.; Malvy D.; Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005-2006: a population-based survey. PLoS One  2008,3(8),e3066","journal-title":"PLoS One"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/qjmed\/hcae028","volume":"117","author":"Ng W.H.","year":"2024","unstructured":"Ng W.H.; Amaral K.; Javelle E.; Mahalingam S.; Chronic chikungunya disease (CCD): clinical insights, immunopathogenesis and therapeutic perspectives. QJM  2024,117(7),489-94","journal-title":"QJM"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"32288","DOI":"10.1038\/srep32288","volume":"6","author":"Ruiz Silva M.","year":"2016 Aug","unstructured":"Ruiz Silva M.; Van Der Ende-Metselaar H.; Mulder H.L.; Smit J.M.; Rodenhuis-Zybert I.A.; Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells. Scientific Reports  2016 Aug,6(1),32288","journal-title":"Scientific Reports"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.4049\/jimmunol.0904181","volume":"184","author":"Her Z.","year":"2010","unstructured":"Her Z.; Malleret B.; Chan M.; Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response. J Immunol  2010,184(10),5903-13","journal-title":"J Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e527","DOI":"10.1371\/journal.pone.0000527","volume":"2","author":"Ozden S.","year":"2007","unstructured":"Ozden S.; Huerre M.; Riviere J.P.; Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One  2007,2(6),e527","journal-title":"PLoS One"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.virol.2009.07.024","volume":"393","author":"Solignat M.","year":"2009","unstructured":"Solignat M.; Gay B.; Higgs S.; Briant L.; Devaux C.; Replication cycle of chikungunya: A re-emerging arbovirus. Virology  2009,393(2),183-97","journal-title":"Virology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/v14081839","volume":"14","author":"Silva J.P.D.C.","year":"2022 Aug 22","unstructured":"Silva J.P.D.C.; Cunha M.D.P.; Pour S.Z.; Hering V.R.; Neto D.F.L.; Zanotto P.M.A.; Chikungunya Virus E2 Structural Protein B-Cell Epitopes Analysis. Viruses  2022 Aug 22,14(8),1839","journal-title":"Viruses"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e11479","DOI":"10.1371\/journal.pone.0011479","volume":"5","author":"Bernard E.","year":"2010","unstructured":"Bernard E.; Solignat M.; Gay B.; Endocytosis of chikungunya virus into mammalian cells: role of clathrin and early endosomal compartments. PLoS One  2010,5(7),e11479","journal-title":"PLoS One"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e0155722","DOI":"10.1128\/jvi.01557-22","volume":"97","author":"Feng F.","year":"2023 May 31","unstructured":"Feng F.; Bouma E.M.; Hu G.; Colocalization of Chikungunya virus with its receptor MXRA8 during Cell Attachment, Internalization, and membrane fusion. Journal of Virology  2023 May 31,97(5),e0155722","journal-title":"Journal of Virology"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e01586-21","DOI":"10.1128\/jvi.01586-21","volume":"96","author":"Rangel M.V.","year":"2022","unstructured":"Rangel M.V.; McAllister N.; Dancel-Manning K.; Noval M.G.; Silva L.A.; Stapleford K.A.; Emerging Chikungunya virus variants at the E1-E1 interglycoprotein spike interface impact virus attachment and inflammation. J Virol  2022,96(4),e01586-21","journal-title":"J Virol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nature09555","volume":"468","author":"Voss J.E.","year":"2010","unstructured":"Voss J.E.; Vaney M.C.; Duquerroy S.; Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature  2010,468(7324),709-712","journal-title":"Nature"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e01561-20","DOI":"10.1128\/JVI.01561-20","volume":"94","author":"Sahoo B.","year":"2020 Nov 9","unstructured":"Sahoo B.; Gudigamolla N.K.; Chowdary T.K.; Acidic pH-Induced Conformational Changes in Chikungunya virus fusion protein E1: a spring-twisted region in the domain I-III linker acts as a hinge point for swiveling motion of domains. J Virol  2020 Nov 9,94(23),e01561-20","journal-title":"J Virol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1038\/s41467-018-07704-x","volume":"9","author":"Chen L.","year":"2018","unstructured":"Chen L.; Wang M.; Zhu D.; Implication for alphavirus host-cell entry and assembly indicated by a 3.5\u00c5 resolution cryo-EM structure. Nat Commun  2018,9(1),5326","journal-title":"Nat Commun"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.chom.2020.07.008","volume":"28","author":"Powell L.A.","year":"2020","unstructured":"Powell L.A.; Miller A.; Fox J.M.; Human mAbs broadly protect against arthritogenic alphaviruses by recognizing conserved nlms of the Mxra8 receptor-binding site. Cell Host Microbe  2020,28(5),699-711.e7","journal-title":"Cell Host Microbe"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e1008876","DOI":"10.1371\/journal.ppat.1008876","volume":"16","author":"Holmes A.C.","year":"2020","unstructured":"Holmes A.C.; Basore K.; Fremont D.H.; Diamond M.S.; A molecular understanding of alphavirus entry. PLoS Pathog  2020,16(10),e1008876","journal-title":"PLoS Pathog"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1006\/viro.1999.0171","volume":"268","author":"Dechecchi M.C.","year":"2000","unstructured":"Dechecchi M.C.; Tamanini A.; Bonizzato A.; Cabrini G.; Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology  2000,268(2),382-390","journal-title":"Virology"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e01500-20","DOI":"10.1128\/JVI.01500-20","volume":"94","author":"McAllister N.","year":"2020","unstructured":"McAllister N.; Liu Y.; Silva L.M.; Chikungunya virus strains from each genetic clade bind sulfated glycosaminoglycans as attachment factors. J Virol  2020,94(24),e01500-20","journal-title":"J Virol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e0005318","DOI":"10.1371\/journal.pntd.0005318","volume":"11","author":"Weber C.","year":"2017","unstructured":"Weber C.; Berberich E.; von Rhein C.; Hen\u00df L.; Hildt E.; Schnierle B.S.; Identification of functional determinants in the Chikungunya virus E2 protein. PLoS Negl Trop Dis  2017,11(1),e0005318","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1126\/science.1066371","volume":"294","author":"Feinberg H.","year":"2001","unstructured":"Feinberg H.; Mitchell D.A.; Drickamer K.; Weis W.I.; Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science  2001,294(5549),2163-6","journal-title":"Science"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"20358","DOI":"10.1074\/jbc.M301284200","volume":"278","author":"Lozach P.Y.","year":"2003","unstructured":"Lozach P.Y.; Lortat-Jacob H.; De Lacroix De Lavalette A.; DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem  2003,278(22),20358-66","journal-title":"J Biol Chem"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1128\/JVI.03184-15","volume":"90","author":"Hoornweg T.E.","year":"2016","unstructured":"Hoornweg T.E.; van Duijl-Richter M.K.S.; Ayala Nu\u00f1ez N.V.; Albulescu I.C.; van Hemert M.J.; Smit J.M.; Dynamics of Chikungunya virus cell entry unraveled by single-virus tracking in living cells. J Virol  2016,90(9),4745-56","journal-title":"J Virol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1085913","DOI":"10.3389\/fcell.2023.1085913","volume":"11","author":"Reyes Ballista J.M.","year":"2023","unstructured":"Reyes Ballista J.M.; Miazgowicz K.L.; Acciani M.D.; Chikungunya virus entry and infectivity is primarily facilitated through cell line dependent attachment factors in mammalian and mosquito cells. Front Cell Dev Biol  2023,11,1085913","journal-title":"Front Cell Dev Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1016\/j.vaccine.2008.03.060","volume":"26","author":"Muthumani K.","year":"2008","unstructured":"Muthumani K.; Lankaraman K.M.; Laddy D.J.; Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine  2008,26(40),5128-34","journal-title":"Vaccine"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e0003800","DOI":"10.1371\/journal.pntd.0003800","volume":"9","author":"Seymour R.L.","year":"2015","unstructured":"Seymour R.L.; Adams A.P.; Leal G.; Alcorn M.D.H.; Weaver S.C.; A Rodent Model of Chikungunya Virus Infection in RAG1 -\/- Mice, with Features of Persistence, for Vaccine Safety Evaluation. PLoS Negl Trop Dis  2015,9(6),e0003800","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/v15051109","volume":"15","author":"Kheirvari M.","year":"2023","unstructured":"Kheirvari M.; Liu H.; Tumban E.; Virus-like particle vaccines and platforms for vaccine development. Viruses  2023,15(5),1109","journal-title":"Viruses"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1016\/j.vaccine.2023.09.022","volume":"41","author":"Schmitz K.S.","year":"2023","unstructured":"Schmitz K.S.; Comvalius A.D.; Nieuwkoop N.J.; A measles virus-based vaccine induces robust chikungunya virus-specific CD4+ T-cell responses in a phase II clinical trial. Vaccine  2023,41(43),6495-504","journal-title":"Vaccine"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.omtn.2022.04.036","volume":"28","author":"Schmidt C.","year":"2022","unstructured":"Schmidt C.; Haefner E.; Gerbeth J.; A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections. Mol Ther Nucleic Acids  2022,28,743-54","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1016\/j.vaccine.2007.01.063","volume":"25","author":"Laddy D.J.","year":"2007","unstructured":"Laddy D.J.; Yan J.; Corbitt N.; Kobasa D.; Kobinger G.P.; Weiner D.B.; Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine  2007,25(16),2984-2989","journal-title":"Vaccine"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"18648","DOI":"10.1073\/pnas.0709198104","volume":"104","author":"Boyer J.D.","year":"2007","unstructured":"Boyer J.D.; Robinson T.M.; Kutzler M.A.; Protection against simian\/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci USA  2007,104(47),18648-53","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1086\/600381","volume":"200","author":"Couderc T.","year":"2009","unstructured":"Couderc T.; Khandoudi N.; Grandadam M.; Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis  2009,200(4),516-23","journal-title":"J Infect Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.virusres.2012.05.004","volume":"167","author":"Khan M.","year":"2012","unstructured":"Khan M.; Dhanwani R.; Rao P.V.L.; Parida M.; Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1\/Th2 response and virus-neutralizing antibodies in mice. Virus Res  2012,167(2),236-46","journal-title":"Virus Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e928","DOI":"10.1371\/journal.pntd.0000928","volume":"5","author":"Mallilankaraman K.","year":"2011","unstructured":"Mallilankaraman K.; Shedlock D.J.; Bao H.; A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis  2011,5(1),e928","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.vaccine.2011.01.108","volume":"29","author":"Wang D.","year":"2011","unstructured":"Wang D.; Suhrbier A.; Penn-Nicholson A.; A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine  2011,29(15),2803-9","journal-title":"Vaccine"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.crimmu.2021.03.001","volume":"2","author":"Amaral M.P.","year":"2021","unstructured":"Amaral M.P.; Coirada F.C.; de Souza Apostolico J.; Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses. Curr Res Immunol  2021,2,23-31","journal-title":"Curr Res Immunol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.4161\/hv.28077","volume":"10","author":"Stenler S.","year":"2014","unstructured":"Stenler S.; Blomberg P.; Smith C.I.E.; Safety and efficacy of DNA vaccines. Hum Vaccin Immunother  2014,10(5),1306-1308","journal-title":"Hum Vaccin Immunother"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.11599\/germs.2013.1034","volume":"3","author":"Khan K.H.","year":"2013","unstructured":"Khan K.H.; DNA vaccines: roles against diseases. Germs  2013,3(1),26-35","journal-title":"Germs"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1128\/JVI.06449-11","volume":"86","author":"Gorchakov R.","year":"2012","unstructured":"Gorchakov R.; Wang E.; Leal G.; Attenuation of Chikungunya virus vaccine strain 181\/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J Virol  2012,86(11),6084-96","journal-title":"J Virol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1016\/j.vaccine.2011.01.076","volume":"29","author":"Partidos C.D.","year":"2011","unstructured":"Partidos C.D.; Weger J.; Brewoo J.; Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine  2011,29(16),3067-73","journal-title":"Vaccine"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1128\/JVI.03116-13","volume":"88","author":"Silva L.A.","year":"2014","unstructured":"Silva L.A.; Khomandiak S.; Ashbrook A.W.; A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization. J Virol  2014,88(5),2385-97","journal-title":"J Virol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0264-410X(86)90003-4","volume":"4","author":"Levitt N.H.","year":"1986","unstructured":"Levitt N.H.; Ramsburg H.H.; Hasty S.E.; Repik P.M.; Cole F.E.; Lupton H.W.; Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine  1986,4(3),157-162","journal-title":"Vaccine"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4269\/ajtmh.1992.47.98","volume":"47","author":"Turell M.J.","year":"1992","unstructured":"Turell M.J.; Malinoski F.J.; Limited potential for mosquito transmission of a live, attenuated chikungunya virus vaccine. Am J Trop Med Hyg  1992,47(1),98-103","journal-title":"Am J Trop Med Hyg"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1128\/JVI.00065-11","volume":"85","author":"Kim D.Y.","year":"2011","unstructured":"Kim D.Y.; Atasheva S.; Foy N.J.; Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype. J Virol  2011,85(9),4363-76","journal-title":"J Virol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/vbz.2006.6.325","volume":"6","author":"Tsetsarkin K.","year":"2006","unstructured":"Tsetsarkin K.; Higgs S.; McGee C.E.; Lamballerie X.D.; Charrel R.N.; Vanlandingham D.L.; Infectious clones of Chikungunya virus (La R\u00e9union isolate) for vector competence studies. Vector Borne Zoonotic Dis  2006,6(4),325-37","journal-title":"Vector Borne Zoonotic Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e1002142","DOI":"10.1371\/journal.ppat.1002142","volume":"7","author":"Plante K.","year":"2011","unstructured":"Plante K.; Wang E.; Partidos C.D.; Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog  2011,7(7),e1002142","journal-title":"PLoS Pathog"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","volume":"62","author":"Edelman R.","year":"2000","unstructured":"Edelman R.; Tacket C.O.; Wasserman S.S.; Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg  2000,62(6),681-5","journal-title":"Am J Trop Med Hyg"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1586\/erv.10.115","volume":"9","author":"Rold\u00e3o A.","year":"2010","unstructured":"Rold\u00e3o A.; Mellado M.C.M.; Castilho L.R.; Carrondo M.J.T.; Alves P.M.; Virus-like particles in vaccine development. Expert Rev Vaccines  2010,9(10),1149-76","journal-title":"Expert Rev Vaccines"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","volume":"31","author":"Kushnir N.","year":"2012","unstructured":"Kushnir N.; Streatfield S.J.; Yusibov V.; Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine  2012,31(1),58-83","journal-title":"Vaccine"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/infdis\/jiw431","volume":"214","author":"Goo L.","year":"2016","unstructured":"Goo L.; Dowd K.A.; Lin T.Y.; A Virus-Like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes. J Infect Dis  2016,214(10),1487-91","journal-title":"J Infect Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12932\/AP-271222-1520","volume":"41","author":"Roongaraya P.","year":"2023","unstructured":"Roongaraya P.; Boonyasuppayakorn S.; Chikungunya vaccines: An update in 2023. Asian Pac J Allergy Immunol  2023,41(1),1-11","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/S1473-3099(22)00226-2","volume":"22","author":"Bennett S.R.","year":"2022","unstructured":"Bennett S.R.; McCarty J.M.; Ramanathan R.; Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis  2022,22(9),1343-55","journal-title":"Lancet Infect Dis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"eade8273","DOI":"10.1126\/scitranslmed.ade8273","volume":"15","author":"Raju S.","year":"2023","unstructured":"Raju S.; Adams L.J.; Earnest J.T.; A chikungunya virus\u2013like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Sci Transl Med  2023,15(696),eade8273","journal-title":"Sci Transl Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nm.2105","volume":"16","author":"Akahata W.","year":"2010","unstructured":"Akahata W.; Yang Z.Y.; Andersen H.; A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med  2010,16(3),334-338","journal-title":"Nat Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","volume":"384","author":"Chang L.J.","year":"2014","unstructured":"Chang L.J.; Dowd K.A.; Mendoza F.H.; Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet  2014,384(9959),2046-52","journal-title":"Lancet"},{"key":"ref=86","year":"2013","unstructured":"Chikungunya virus vaccine trial in healthy adults.  Available from:  https:\/\/clinicaltrials.gov\/study\/NCT014893582013"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jama.2020.2477","volume":"323","author":"Chen G.L.","year":"2020","unstructured":"Chen G.L.; Coates E.E.; Plummer S.H.; Effect of a Chikungunya virus\u2013like particle vaccine on safety and tolerability outcomes. JAMA  2020,323(14),1369-77","journal-title":"JAMA"},{"key":"ref=88","year":"2018","unstructured":"Trial for safety and immunogenicity of a Chikungunya vaccine, VRC-CHKVLP059-00-VP, in healthy adults.  Available from:  https:\/\/clinicaltrials.gov\/study\/NCT025624822018"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"655743","DOI":"10.3389\/fimmu.2021.655743","volume":"12","author":"Zhao Z.","year":"2021","unstructured":"Zhao Z.; Deng Y.; Niu P.; Co-Immunization with CHIKV VLP and DNA vaccines induces a promising humoral response in mice. Front Immunol  2021,12,655743","journal-title":"Front Immunol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1016\/j.vaccine.2012.07.072","volume":"30","author":"Kumar M.","year":"2012","unstructured":"Kumar M.; Sudeep A.B.; Arankalle V.A.; Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine  2012,30(43),6142-9","journal-title":"Vaccine"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3390\/microorganisms10071450","volume":"10","author":"Deng S.","year":"2022","unstructured":"Deng S.; Liang H.; Chen P.; Viral vector vaccine development and application during the COVID-19 pandemic. Microorganisms  2022,10(7),1450","journal-title":"Microorganisms"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1016\/j.vaccine.2007.01.064","volume":"25","author":"Zuniga A.","year":"2007","unstructured":"Zuniga A.; Wang Z.; Liniger M.; Attenuated measles virus as a vaccine vector. Vaccine  2007,25(16),2974-83","journal-title":"Vaccine"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","volume":"31","author":"Brandler S.","year":"2013","unstructured":"Brandler S.; Ruffi\u00e9 C.; Combredet C.; A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine  2013,31(36),3718-25","journal-title":"Vaccine"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.1128\/JVI.72.9.7420-7427.1998","volume":"72","author":"Mrkic B.","year":"1998","unstructured":"Mrkic B.; Pavlovic J.; R\u00fclicke T.; Measles virus spread and pathogenesis in genetically modified mice. J Virol  1998,72(9),7420-7","journal-title":"J Virol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/infdis\/jiz202","volume":"220","author":"Rossi S.L.","year":"2019","unstructured":"Rossi S.L.; Comer J.E.; Wang E.; Immunogenicity and efficacy of a measles virus-vectored Chikungunya vaccine in nonhuman primates. J Infect Dis  2019,220(5),735-42","journal-title":"J Infect Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","volume":"15","author":"Ramsauer K.","year":"2015","unstructured":"Ramsauer K.; Schwameis M.; Firbas C.; Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis  2015,15(5),519-527","journal-title":"Lancet Infect Dis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","volume":"392","author":"Reisinger E.C.","year":"2018","unstructured":"Reisinger E.C.; Tschismarov R.; Beubler E.; Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet  2018,392(10165),2718-2727","journal-title":"Lancet"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e0003684","DOI":"10.1371\/journal.pntd.0003684","volume":"9","author":"Weber C.","year":"2015","unstructured":"Weber C.; B\u00fcchner S.M.; Schnierle B.S.; A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice. PLoS Negl Trop Dis  2015,9(4),e0003684","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1128\/JVI.03418-13","volume":"88","author":"Garc\u00eda-Arriaza J.","year":"2014","unstructured":"Garc\u00eda-Arriaza J.; Cepeda V.; Halleng\u00e4rd D.; A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol  2014,88(6),3527-47","journal-title":"J Virol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","volume":"12","author":"Folegatti P.M.","year":"2021","unstructured":"Folegatti P.M.; Harrison K.; Preciado-Llanes L.; A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nat Commun  2021,12(1),4636","journal-title":"Nat Commun"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/v11040322","volume":"11","author":"L\u00f3pez-Camacho C.","year":"2019","unstructured":"L\u00f3pez-Camacho C.; Kim Y.C.; Blight J.; Assessment of immunogenicity and neutralisation efficacy of viral-vectored vaccines against chikungunya virus. Viruses  2019,11(4),322","journal-title":"Viruses"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/pathogens8040231","volume":"8","author":"Campos R.K.","year":"2019","unstructured":"Campos R.K.; Preciado-Llanes L.; Azar S.R.; Lopez-Camacho C.; Reyes-Sandoval A.; Rossi S.L.; A single and un-adjuvanted dose of a chimpanzee adenovirus-vectored vaccine against chikungunya virus fully protects mice from lethal disease. Pathogens  2019,8(4),231","journal-title":"Pathogens"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1128\/JVI.01860-12","volume":"87","author":"Chattopadhyay A.","year":"2013","unstructured":"Chattopadhyay A.; Wang E.; Seymour R.; Weaver S.C.; Rose J.K.; A chimeric vesiculo\/alphavirus is an effective alphavirus vaccine. J Virol  2013,87(1),395-402","journal-title":"J Virol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","volume":"27","author":"Li Y.D.","year":"2020","unstructured":"Li Y.D.; Chi W.Y.; Su J.H.; Ferrall L.; Hung C.F.; Wu T.C.; Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci  2020,27(1),104","journal-title":"J Biomed Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1016\/j.vaccine.2023.04.064","volume":"41","author":"Shaw C.A.","year":"2023","unstructured":"Shaw C.A.; August A.; Bart S.; A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine  2023,41(26),3898-906","journal-title":"Vaccine"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijid.2018.11.058","volume":"79","author":"Shaw C.","year":"2019","unstructured":"Shaw C.; Panther L.; August A.; Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial. Int J Infect Dis  2019,79,17","journal-title":"Int J Infect Dis"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"August A.","year":"2021","unstructured":"August A.; Attarwala H.Z.; Himansu S.; A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med  2021,27(12),2224-33","journal-title":"Nat Med"},{"key":"ref=108","year":"2019","unstructured":"Safety, Tolerability, and immunogenicity of val-181388 in healthy participants.  Available from:  https:\/\/clinicaltrials.gov\/study\/NCT033250752019"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1056\/NEJMra1406035","volume":"372","author":"Weaver S.C.","year":"2015","unstructured":"Weaver S.C.; Lecuit M.; Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med  2015,372(13),1231-9","journal-title":"N Engl J Med"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"9888","DOI":"10.1128\/JVI.00956-12","volume":"86","author":"Rudd P.A.","year":"2012","unstructured":"Rudd P.A.; Wilson J.; Gardner J.; Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock. J Virol  2012,86(18),9888-9898","journal-title":"J Virol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1084\/jem.20090851","volume":"207","author":"Schilte C.","year":"2010","unstructured":"Schilte C.; Couderc T.; Chretien F.; Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med  2010,207(2),429-442","journal-title":"J Exp Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"S506","DOI":"10.1093\/infdis\/jiw324","volume":"214","author":"Clayton A.M.","year":"2016","unstructured":"Clayton A.M.; Monoclonal antibodies as prophylactic and therapeutic agents against chikungunya virus. J Infect Dis  (Suppl. 5)2016,214,S506-S509","journal-title":"J Infect Dis"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1128\/JVI.02364-15","volume":"90","author":"Porta J.","year":"2016","unstructured":"Porta J.; Mangala Prasad V.; Wang C.I.; Akahata W.; Ng L.F.P.; Rossmann M.G.; Structural studies of Chikungunya virus-like particles complexed with human antibodies: neutralization and cell-to-cell transmission. J Virol  2016,90(3),1169-77","journal-title":"J Virol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/infdis\/jis674","volume":"207","author":"Fric J.","year":"2013","unstructured":"Fric J.; Bertin-Maghit S.; Wang C.I.; Nardin A.; Warter L.; Use of human monoclonal antibodies to treat Chikungunya virus infection. J Infect Dis  2013,207(2),319-22","journal-title":"J Infect Dis"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"e2423","DOI":"10.1371\/journal.pntd.0002423","volume":"7","author":"Selvarajah S.","year":"2013","unstructured":"Selvarajah S.; Sexton N.R.; Kahle K.M.; A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis  2013,7(9),e2423","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.celrep.2015.11.043","volume":"13","author":"Jin J.","year":"2015","unstructured":"Jin J.; Liss N.M.; Chen D.H.; Neutralizing monoclonal antibodies block Chikungunya virus entry and release by targeting an epitope critical to viral pathogenesis. Cell Rep  2015,13(11),2553-64","journal-title":"Cell Rep"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/v11040305","volume":"11","author":"Jin J.","year":"2019","unstructured":"Jin J.; Simmons G.; Antiviral functions of monoclonal antibodies against Chikungunya virus. Viruses  2019,11(4),305","journal-title":"Viruses"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"e1003312","DOI":"10.1371\/journal.ppat.1003312","volume":"9","author":"Pal P.","year":"2013","unstructured":"Pal P.; Dowd K.A.; Brien J.D.; Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog  2013,9(4),e1003312","journal-title":"PLoS Pathog"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"8213","DOI":"10.1128\/JVI.01032-14","volume":"88","author":"Pal P.","year":"2014","unstructured":"Pal P.; Fox J.M.; Hawman D.W.; Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol  2014,88(15),8213-26","journal-title":"J Virol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"e0005637","DOI":"10.1371\/journal.pntd.0005637","volume":"11","author":"Broeckel R.","year":"2017","unstructured":"Broeckel R.; Fox J.M.; Haese N.; Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. PLoS Negl Trop Dis  2017,11(6),e0005637","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.cell.2015.10.050","volume":"163","author":"Fox J.M.","year":"2015","unstructured":"Fox J.M.; Long F.; Edeling M.A.; Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell  2015,163(5),1095-107","journal-title":"Cell"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"e2100104118","DOI":"10.1073\/pnas.2100104118","volume":"118","author":"Malonis R.J.","year":"2021","unstructured":"Malonis R.J.; Earnest J.T.; Kim A.S.; Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses. Proc Natl Acad Sci USA  2021,118(37),e2100104118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"27637","DOI":"10.1073\/pnas.2008051117","volume":"117","author":"Zhou Q.F.","year":"2020","unstructured":"Zhou Q.F.; Fox J.M.; Earnest J.T.; Structural basis of Chikungunya virus inhibition by monoclonal antibodies. Proc Natl Acad Sci USA  2020,117(44),27637-27645","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"eaaw6647","DOI":"10.1126\/sciimmunol.aaw6647","volume":"4","author":"Kose N.","year":"2019","unstructured":"Kose N.; Fox J.M.; Sapparapu G.; A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol  2019,4(35),eaaw6647","journal-title":"Sci Immunol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.chom.2015.08.002","volume":"18","author":"Smith S.A.","year":"2015","unstructured":"Smith S.A.; Silva L.A.; Fox J.M.; Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against Chikungunya virus. Cell Host Microbe  2015,18(3),382","journal-title":"Cell Host Microbe"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.antiviral.2011.03.182","volume":"90","author":"Delogu I.","year":"2011","unstructured":"Delogu I.; Pastorino B.; Baronti C.; Nougair\u00e8de A.; Bonnet E.; de Lamballerie X.; In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res  2011,90(3),99-107","journal-title":"Antiviral Res"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/v12030314","volume":"12","author":"Albulescu I.C.","year":"2020","unstructured":"Albulescu I.C.; White-Scholten L.; Tas A.; Suramin inhibits Chikungunya virus replication by interacting with virions and blocking the early steps of infection. Viruses  2020,12(3),314","journal-title":"Viruses"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.antiviral.2018.10.005","volume":"159","author":"Ho Y.J.","year":"2018","unstructured":"Ho Y.J.; Liu F.C.; Yeh C.T.; Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms. Antiviral Res  2018,159,134-142","journal-title":"Antiviral Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"e0126360","DOI":"10.1371\/journal.pone.0126360","volume":"10","author":"Rothan H.A.","year":"2015","unstructured":"Rothan H.A.; Bahrani H.; Mohamed Z.; A combination of doxycycline and ribavirin alleviated chikungunya infection. PLoS One  2015,10(5),e0126360","journal-title":"PLoS One"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"e01788-20","DOI":"10.1128\/AAC.01788-20","volume":"64","author":"Kovacikova K.","year":"2020","unstructured":"Kovacikova K.; van Hemert M.J.; Small-Molecule inhibitors of chikungunya virus: mechanisms of action and antiviral drug resistance. Antimicrob Agents Chemother  2020,64(12),e01788-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/pin.13198","volume":"72","author":"Ichihara R.","year":"2022","unstructured":"Ichihara R.; Shiraki Y.; Mizutani Y.; Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer. Pathol Int  2022,72(3),161-175","journal-title":"Pathol Int"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1094612","DOI":"10.3389\/fonc.2022.1094612","volume":"12","author":"Tan L.","year":"2023 Jan 10","unstructured":"Tan L.; Fu D.; Liu F.; MXRA8 is an immune-relative prognostic biomarker associated with metastasis and CD8+ T cell infiltration in colorectal cancer. Frontiers in Oncology  2023 Jan 10,12,1094612","journal-title":"Frontiers in Oncology"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501436868260120100843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/251390\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501436868260120100843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:40:54Z","timestamp":1790145654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/251390\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":132,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501436868260120100843","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}